Vizimpro (dacomitinib) is a small molecule pharmaceutical. Dacomitinib was first approved as Vizimpro on 2018-09-27. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target receptor tyrosine-protein kinase erbB-4, epidermal growth factor receptor, and receptor tyrosine-protein kinase erbB-2. Vizimpro's patents are valid until 2028-08-26 (FDA).
|Indication||non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors|